On Monday, many investors drew an X next to the name of Nano-X Imaging (NASDAQ: NNOX), also known as Nanox. The next-generation medical imaging specialist experienced a sell-off following its latest earnings release that morning, and by the end of the day, its price had fallen by almost 5%. That didn't compare well to the S&P 500's (SNPINDEX: ^GSPC) 0.6% increase.
Before market open, Nanox unveiled its fourth-quarter results, which showed that the company booked $3 million in revenue, which was an improvement over the $2.4 million it collected in the same period of 2023. On the bottom line, however, the specialty healthcare company's net loss deepened. It came in at $14.1 million ($0.23 per share), against the year-ago deficit of $10.2 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Few analysts track Nanox stock. Regardless, according to data compiled by The Wall Street Journal, collectively they were anticipating a slightly narrower net loss of $0.22 per share.
In its earnings release, Nanox attributed the deeper bottom-line shortfall to a one-time, $3 million income item that was booked in the third quarter. In more positive developments, Nanox provided a business update showcasing its two recent regulatory approvals.
The first, earned in December, was the Food and Drug Administration's (FDA) nod for its Nanox.ARC, indicated for general use, and the second was the granting of a CE mark for the same system this past February. This is a quality designation required to sell products in most European countries.
Another development in Nanox's favor was its cash position. The company reported that it had cash, equivalents, and other fairly liquid assets totaling $83.5 million at the end of last year. This was slightly higher than the $82.8 million at the conclusion of 2023, indicating that management is doing a good job of conserving those precious resources.
Before you buy stock in Nano-X Imaging, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nano-X Imaging wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $672,177!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of March 24, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.